ClinicalTrials.gg

Program

ziftomenib

Also written as “Ziftomenib”.

Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Gastrointestinal Stromal Tumors · Hematologic Neoplasms, led by 2 companies.

Furthest: phase 3, since May 16, 20256 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kura Oncology55 open or runningphase 3since May 16, 2025Jun 25, 2019Dec 2026phase 1 · NCT06001788
Kyowa Kirin11 open or runningphase 2since Apr 8, 2026Apr 8, 2026Mar 2027phase 2 · NCT07623616

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 25, 2019First study: phase 2 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT04067336 · 263 enrolled · United States, Belgium, Canada and more
  2. Aug 7, 2023Phase 1 study in Hematologic NeoplasmsKura Oncology · NCT06001788 · 171 planned · United States, Italy, Spain
  3. Oct 14, 2024Phase 1 study in Gastrointestinal Stromal TumorsKura Oncology · NCT06655246 · 135 planned · United States
  4. May 16, 2025Phase 3 study in Leukemia, Myeloid, AcuteKura Oncology · NCT07007312 · 1,300 planned · United States, Australia, Belgium and more
  5. Apr 8, 2026Kyowa Kirin's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to Kyowa KirinKyowa Kirin · NCT07623616 · 6 planned · Japan
  6. Oct 21, 2026Phase 1 study in Myelodysplastic SyndromesKura Oncology · NCT07929740 · 126 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Hematologic NeoplasmsKura Oncology · NCT06001788
  2. Mar 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteKyowa Kirin · NCT07623616
  3. Oct 16, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteKura Oncology · NCT04067336
  4. Feb 28, 2029Primary completion: phase 1 study in Myelodysplastic SyndromesKura Oncology · NCT07929740

TargetBeta

KMT2A →read by rule
“An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, ”NCIt, by rule

Other programs on KMT2A

ProgramCompanyFurthest phaseStudies
revumenibruleSyndax Pharmaceuticalsphase 36
bleximenibJohnson & Johnsonphase 34
icovamenibrulebiomea-fusion-incphase 27

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07929740Myelodysplastic Syndromes1Not yet recruitingKura OncologyFeb 28, 2029126
NCT07623616Leukemia, Myeloid, Acute · Japan2RecruitingKyowa KirinMar 20276
NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3RecruitingKura OncologyNov 20311,300
NCT06655246Gastrointestinal Stromal Tumors · United States1RecruitingKura OncologyJun 2029135
NCT06001788Hematologic Neoplasms · United States, Italy, Spain1RecruitingKura OncologyDec 2026171
NCT04067336Leukemia, Myeloid, Acute · United States, Belgium, Canada and more2Active, not recruitingKura OncologyOct 16, 2028263

How it is read

Names in the registry

  • “Ziftomenib”, 7 entries
  • “ziftomenib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.